Article
A RET::GRB2 fusion in pheochromocytoma defies the classic paradigm of RET oncogenic fusions.
Cell reports. Medicine - 19 Jul 2022
Estrada-Zuniga Cynthia M, Cheng Zi-Ming, Ethiraj Purushoth, Guo Qianjin, Gonzalez-Cantú Hector, Adderley Elaina, Lopez Hector, Landry Bethany N, Zainal Abir, Aronin Neil, Ding Yanli, Wang Xiaojing, Aguiar Ricardo C T, Dahia Patricia L M
Abstract excerpt
The RET kinase receptor is a target of mutations in neural crest tumors, including pheochromocytomas, and of oncogenic fusions in epithelial cancers. We report a RET::GRB2 fusion in a pheochromocytoma in which RET, functioning as the upstream partner, retains its kinase domain but loses critical C-terminal motifs and is fused to GRB2, a physiological RET interacting protein. RET::GRB2 is an oncogenic driver that...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.